Cargando…
Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer
With proven efficacy of the use of immunotherapy in almost all stages of NSCLC, immunotherapy toxicity has become a very important topic that requires immediate recognition and management. The diagnosis of toxicities associated with immunotherapy in lung cancer can be very challenging and often requ...
Autores principales: | Burke, Michael, Rashdan, Sawsan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514873/ https://www.ncbi.nlm.nih.gov/pubmed/34660286 http://dx.doi.org/10.3389/fonc.2021.720759 |
Ejemplares similares
-
The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer
por: Kalra, Anjali, et al.
Publicado: (2023) -
Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
por: Daniello, Lea, et al.
Publicado: (2021) -
Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer
por: Hou, Wanting, et al.
Publicado: (2021) -
Peripheral absolute eosinophil count identifies the risk of serious immune-related adverse events in non-small cell lung cancer
por: Wu, Yan, et al.
Publicado: (2022) -
Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer
por: Tao, Ye, et al.
Publicado: (2023)